» An Experts’ Forum in Tokyo and Singapore on DDR and PARP inhibition

DDR and PARPi Expert Forums were held with international faculty in Tokyo and Singapore during January 2020.

Learn about the role of PARP inhibitors in clinical practice and targeting DDR, including:

Mechanism of Action of PARP inhibition and targeting DDR
Clinical profile of PARP inhibitors and their benefit in ovarian and breast cancer
Appropriate patient selection for PARP inhibition
Future DDR and PARP inhibition

Prof. Keiichi Fujiwara has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, AstraZeneca, Clovis, Eisai, MSD, Ono, Pfizer and Takeda.

Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Artios Pharma Ltd.

Dr Shinji Ohno has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Chugai, Eisai, Eli Lilly, KyowaHakko, Kirin and Taiho

Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.

Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.